Trial 9L-22-1


A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Biological Response Modifier, Immunotherapy
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Abdullah Ladha, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M., Sana Mutalib, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.